通过合理联合策略克服B淋巴细胞白血病对靶向治疗和免疫治疗的耐药性
Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies.
作者信息
Quijada-Álamo Miguel, Freed Grace, Wagenblast Elvin
机构信息
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Blood Cancer Discov. 2025 Jul 1;6(4):293-297. doi: 10.1158/2643-3230.BCD-25-0036.
Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.
尽管靶向治疗和免疫治疗在B细胞急性淋巴细胞白血病（B-ALL）中具有显著疗效，但复发和难治性病例仍然是一个重大挑战。在本综述中，我们讨论了将靶向药物与免疫疗法相结合如何有助于克服耐药性并改善B-ALL患者的长期预后。
Zotero 插件